Clinical Trial Update: A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies [Phase 2]

View source ↗

Summary

Phase 2 study of ianalumab (VAY736) in patients with primary immune thrombocytopenia who have had at least two prior therapies; the trial is currently active bu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Ianalumab (VAY736) (ianalumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Primary Immune Thrombocytopenia (ITP) | Phase 2 | Status: ACTIVE_NOT_RECRUITING